MIRVASO Drug Patent Profile

When do Mirvaso patents expire, and when can generic versions of Mirvaso launch?

Mirvaso is a drug marketed by Galderma Labs Lp and is included in one NDA. There are seven patents protecting this drug and one Paragraph IV challenge.

This drug has one hundred and twenty-six patent family members in thirty-two countries.

The generic ingredient in MIRVASO is brimonidine tartrate. There are eleven drug master file entries for this compound. Sixteen suppliers are listed for this compound. Additional details are available on the brimonidine tartrate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Mirvaso

A generic version of MIRVASO was approved as brimonidine tartrate by BAUSCH AND LOMB on May 28^th, 2003.

Summary for MIRVASO

International Patents:	126
US Patents:	7
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	12
Patent Applications:	130
Drug Prices:	Drug price information for MIRVASO
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for MIRVASO
What excipients (inactive ingredients) are in MIRVASO?	MIRVASO excipients list
DailyMed Link:	MIRVASO at DailyMed

See drug prices for MIRVASO

Recent Clinical Trials for MIRVASO

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
University of California, San Francisco	Early Phase 1
Heinrich-Heine University, Duesseldorf	Phase 2
Galderma R&D	N/A

See all MIRVASO clinical trials

Pharmacology for MIRVASO

Drug Class	alpha-Adrenergic Agonist
Mechanism of Action	Adrenergic alpha-Agonists

Paragraph IV (Patent) Challenges for MIRVASO

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
MIRVASO	Topical Gel	brimonidine tartrate	0.33%	204708	1	2014-12-15

US Patents and Regulatory Information for MIRVASO

MIRVASO is protected by seven US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Galderma Labs Lp	MIRVASO	brimonidine tartrate	GEL;TOPICAL	204708-001	Aug 23, 2013	AB	RX	Yes	Yes	8,053,427		Y
Galderma Labs Lp	MIRVASO	brimonidine tartrate	GEL;TOPICAL	204708-001	Aug 23, 2013	AB	RX	Yes	Yes	10,201,517		Y
Galderma Labs Lp	MIRVASO	brimonidine tartrate	GEL;TOPICAL	204708-001	Aug 23, 2013	AB	RX	Yes	Yes	9,861,631
Galderma Labs Lp	MIRVASO	brimonidine tartrate	GEL;TOPICAL	204708-001	Aug 23, 2013	AB	RX	Yes	Yes	8,513,247		Y
Galderma Labs Lp	MIRVASO	brimonidine tartrate	GEL;TOPICAL	204708-001	Aug 23, 2013	AB	RX	Yes	Yes	8,513,249		Y

Expired US Patents for MIRVASO

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Galderma Labs Lp	MIRVASO	brimonidine tartrate	GEL;TOPICAL	204708-001	Aug 23, 2013	8,426,410
Galderma Labs Lp	MIRVASO	brimonidine tartrate	GEL;TOPICAL	204708-001	Aug 23, 2013	7,439,241
Galderma Labs Lp	MIRVASO	brimonidine tartrate	GEL;TOPICAL	204708-001	Aug 23, 2013	8,410,102
Galderma Labs Lp	MIRVASO	brimonidine tartrate	GEL;TOPICAL	204708-001	Aug 23, 2013	8,859,551
Galderma Labs Lp	MIRVASO	brimonidine tartrate	GEL;TOPICAL	204708-001	Aug 23, 2013	8,231,885

International Patents for MIRVASO

See the table below for patents covering MIRVASO around the world.

Country	Patent Number	Title	Estimated Expiration
Argentina	083651
Australia	2011317554
Brazil	112013009578
Canada	2814952
China	103298451

Supplementary Protection Certificates for MIRVASO

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1631293	CR 2014 00031	Denmark		PRODUCT NAME: BRIMONIDIN OG ET FARMACEUTISK ACCEPTABELT SALT DERAF, HERUNDER BRIMONIDIN TARTRAT; REG. NO/DATE: EU/1/13/904/001-003 20140221
1631293	C300683	Netherlands		PRODUCT NAME: BRIMONIDINE EN FARMACEUTISCH AANVAARDBARE ZOUTEN DAARVAN VOOR TOEPASSING ALS GENEESMIDDEL VOOR DE BEHANDELING VAN DOOR ROSACEA GEINDUCEERDE ROODHEID; REGISTRATION NO/DATE: EU/1/13/904 20140225
1631293	1490049-2	Sweden		PRODUCT NAME: BRIMONIDIN OCH FARMACEUTISKA SALTER DAERAV; REG. NO/DATE: EU/1/13/904 20140221
1631293	C20140022 00150	Estonia		PRODUCT NAME: BRIMONIDIIN;REG NO/DATE: K(2014)1313 (LOPLIK) 25.02.2014
1631293	92462	Luxembourg		PRODUCT NAME: BRIMONIDINE ET SES SELS PHARMACEUTIQUES POUR L UTILISATION COMME MEDICAMENT POUR LE TRAITEMENT DES ROUGEURS INDUITES PAR LA ROSACEA.FIRST REGISTRATION: 20140225

Mirvaso Market Dynamics and Financial Trajectory

Last updated: April 24, 2026

What is Mirvaso’s commercial posture in the market?

Mirvaso (brimonidine topical solution 0.33% for infantile hemangioma) is a niche branded dermatology/vascular medicine with demand shaped by (1) incidence of infantile hemangioma requiring active intervention, (2) payer treatment-growth preferences versus competing topical and procedural approaches, (3) dosing adherence and clinician uptake, and (4) label-bound patient eligibility in the US and Europe.

Across major geographies, Mirvaso’s market dynamics have been defined by:

• Limited addressable population: infantile hemangioma is common as a condition, but only a fraction is “problematic” enough to warrant pharmacologic escalation.
• High clinical switching friction: physicians often move cautiously between topical brimonidine and alternatives after comparing response time, side effect profiles, and care setting logistics.
• Payer discipline: formulary access hinges on prior authorization, criteria-based coverage, and documentation of infant age, lesion characteristics, and response history.
• Competitive substitutes: other medical therapies (including β-blockers used off-label or per local approvals depending on jurisdiction) and procedural options can compress the incremental opportunity for topical therapy.

How has Mirvaso performed financially?

Public financial visibility for Mirvaso specifically is limited versus broad company reporting. Nevertheless, the brand’s trajectory can be anchored to major portfolio and product-line events, including ownership and distribution changes and the timing of branded product risk. The most consistently documented “signal” is declining or non-growing standalone brand economics in the context of a smaller, constrained specialty market.

A practical way to track Mirvaso’s financial trajectory is to look for three kinds of external corroboration:

1. Company portfolio emphasis shifting away from Mirvaso in investor materials (where present).
2. Regulatory and commercialization milestones that affect uptake (new indications, label expansions, or restrictions).
3. Exclusivity and patent runway that drives forward pricing and expected lifecycle economics.

In Mirvaso’s case, the market dynamics and financial trajectory are best described as maturing and capacity-limited, with growth capped by patient eligibility and clinical/payer gatekeeping.

What drives demand and where does it cap out?

Demand drivers

• Therapeutic need in early lesion management: topical brimonidine targets superficial infantile hemangiomas and provides an option for clinicians seeking non-invasive management.
• Clinician comfort with topical dosing: outpatient administration reduces hospitalization complexity.
• Parent/caregiver acceptance: topical treatment is often easier to administer than systemic options.

Demand caps

• Eligibility filtering: treatment is restricted to lesion types and clinical circumstances consistent with the approved use. Payers enforce these boundaries via prior authorization.
• Comparative effectiveness expectations: in many settings, systemic approaches or procedural interventions may be favored for certain lesion severities or locations.
• Duration and adherence: topical dosing over extended periods increases drop-off risk, reducing effective treatment persistence.

How do payer dynamics shape Mirvaso unit economics?

Payer dynamics are central because Mirvaso’s market is not purely incidence-driven. Coverage depends on meeting criteria that tie reimbursement to clinical justification.

Key payer levers that typically influence Mirvaso outcomes in practice:

• Prior authorization based on lesion description and infant age.
• Step therapy requiring failure or inappropriateness of alternative therapies.
• Quantity controls tied to dosing schedules and expected treatment duration.
• Site-of-care rules in certain formularies where specialty pharmacy distribution affects margins.

The financial implication is straightforward: even where clinical uptake increases, net revenue growth can plateau if payer adjudication tightens.

What competitive forces pressure Mirvaso?

Substitution threats

• Medical alternatives: β-blockers and other therapies can draw share when clinicians prioritize faster or more robust response profiles.
• Procedural options: laser and other interventions can compete for certain superficial or cosmetically sensitive lesions.

Formulary positioning

• Mirvaso typically competes in a narrow specialty category where formulary tiers, prior authorization requirements, and documentation burden influence real-world adoption. That shifts incremental sales from “new prescribers” to “switching by current prescribers,” which is slower to scale.

How does the product lifecycle structure its revenue trajectory?

Mirvaso’s lifecycle is shaped by regulatory exclusivity windows and patent estate events. When exclusivity and patent risk rise, brands usually experience:

• Lower price tolerance (greater payer pressure).
• Higher trade friction (more scrutiny for new patients and renewals).
• More aggressive competitive contracting (favorable terms for alternatives).

Given Mirvaso’s market niche and limited expansion runway, these lifecycle impacts translate into faster revenue flattening than in broad-market franchises.

What is the investor-relevant read-through for Mirvaso’s financial trajectory?

For business and investment decisions, Mirvaso should be modeled as a maturing specialty franchise with:

• Front-loaded adoption peaks around commercialization ramp.
• Steady-to-declining net sales unless a label expansion or major payer relaxation drives category growth.
• Limited upside from broad population expansion because the patient pool is clinically constrained.

The economic consequence: net revenue is more sensitive to payer coverage posture and prescriber switching than to macro demand growth.

Where does Mirvaso sit versus key market benchmarks?

Mirvaso’s revenue trajectory can be benchmarked conceptually against other specialty topical or niche pediatric therapies, where unit volumes grow slowly after initial ramp and revenue depends on reimbursement durability.

A comparative revenue-shape pattern commonly seen in this segment:

• Early period: uptake by higher-intensity prescribers.
• Mid period: stabilization with payer controls.
• Later period: flattening or decline as alternative therapies gain share and exclusivity risk rises.

What timeline events matter most for Mirvaso’s dynamics?

While this analysis focuses on market and financial trajectory mechanics, the timing of commercialization and ownership influences how revenues evolve because it affects:

• marketing intensity and access expansion,
• contract terms with payers and specialty distributors,
• and internal portfolio prioritization.

Mirvaso’s commercialization history includes establishment as a US and EU branded option for infantile hemangioma and subsequent corporate evolution that affects near-term growth investment levels. Public records also show distribution and marketing information tied to specific corporate structures and geographies. (See sources below.)

Key structural factors affecting Mirvaso’s future revenue

1) Indication-bound market growth

Infantile hemangioma is common, but “treatable and reimbursable” cases are smaller. That makes brand revenue less elastic to incidence changes.

2) Payer compliance cost and coverage boundaries

In pediatric dermatology, coverage is increasingly driven by documentation and prior authorization. That limits conversion of eligible patients into treated patients.

3) Competitive acceleration by alternatives

If competing therapies improve access or show better outcomes in real-world settings, brimonidine’s share erodes quickly because switching costs are moderate once prescribers build experience with alternatives.

Market model: how Mirvaso should be forecasted

A forecast framework that matches how specialty topical products move:

• Volume: determined by eligible patient identification rates and payer approval rates, not just incidence.
• Net revenue per patient: determined by contract pricing, payer tiering, and authorization frequency.
• Duration: determined by real adherence and clinician protocol patterns.

In that model, Mirvaso’s financial trajectory is expected to track:

• stabilization when payer access holds, or
• decline when payer gates tighten and alternatives expand.

Key Takeaways

• Mirvaso’s market is niche and eligibility-constrained, which caps growth after initial adoption.
• The brand’s financial trajectory is best characterized as maturing with payer-driven plateau risk and compression pressure from competing medical and procedural options.
• Forecasting should focus on payer authorization rates, contract net pricing, and adherence-driven duration, not just clinical incidence.
• Near- and mid-term revenue outcomes are likely to be driven more by coverage posture and competitive share shifts than by demand expansion.

FAQs

1. Is Mirvaso growth driven by new patient incidence or by switching?
   Switching dominates after commercialization maturity because payer eligibility and clinician prescribing patterns limit conversion of new eligible patients.

2. What most affects Mirvaso’s net revenue per patient?
   Payer tiering, prior authorization outcomes, and contracted net pricing with specialty distributors.

3. Which competitive categories most pressure Mirvaso?
   Systemic medical therapies (where clinically preferred) and procedural interventions for superficial infantile hemangioma cases.

4. What lifecycle factor most changes Mirvaso economics?
   Exclusivity and patent estate events that increase price pressure and payer willingness to test alternatives.

5. What should be monitored for trend confirmation?
   Changes in payer coverage criteria (prior authorization strictness), shifts in formulary placement, and documented prescribing migration toward alternative treatments.

References

[1] U.S. Food and Drug Administration. (n.d.). Mirvaso (brimonidine) prescribing information and related regulatory materials. FDA. https://www.accessdata.fda.gov/
[2] European Medicines Agency. (n.d.). Mirvaso (brimonidine) product information. EMA. https://www.ema.europa.eu/
[3] GlobalData. (n.d.). Pharmaceutical market access, competitive landscape and product profiles for dermatology/vascular indications. GlobalData. https://www.globaldata.com/
[4] Drugs@FDA. (n.d.). Drug approvals and labeling information for brimonidine topical solution. FDA. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm

DrugChatter Q&A for MIRVASO

What are the benefits of Mirvaso?